NEW YORK (360Dx) – Proteomic diagnostics firm Prevencio has released a research-use-only version of its HART cardiovascular biomarker panels and is planning to launch laboratory-developed tests for predicting the presence of obstructive coronary artery disease (HART CAD) and predicting major adverse cardiac events (HART CVE) in either late 2018 or early 2019.

The company also this week presented data at the American Diabetes Association 2018 Scientific Sessions demonstrating that its HART CAD and HART CVE tests are as effective in diabetic patients as in patients without diabetes.